Want to see VNRX full AI Analyst Report?
Top Page
VolitionRX
(VNRX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.78
▼(-8.35% Downside)
Action:Reiterated
Date:08/02/26
The score is held down primarily by weak financial performance (very large losses, negative equity, and sustained cash burn) and bearish technical positioning (price far below key moving averages). Offsetting these are earnings-call positives around scientific/commercial milestones and strong YoY revenue growth, but near-term visibility remains limited due to lumpy revenue, no formal guidance, and continued reliance on external financing, reinforced by recent convertible-note related events.
Positive Factors
Revenue growth with solid gross margins
Sustained double-digit revenue growth and a ~60% gross margin indicate the company’s products exhibit attractive unit economics. If commercialization and reimbursement progress continue, these margins support scalable gross-profit expansion as volumes rise, aiding long-term margin sustainability.
Negative Factors
Large and persistent cash burn
Ongoing multi‑million negative operating and free cash flow means the business lacks self‑funding capacity and will repeatedly need external capital to sustain operations. This constrains strategic choices, risks dilution, and makes long‑term execution dependent on financing availability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth with solid gross margins
Sustained double-digit revenue growth and a ~60% gross margin indicate the company’s products exhibit attractive unit economics. If commercialization and reimbursement progress continue, these margins support scalable gross-profit expansion as volumes rise, aiding long-term margin sustainability.
Read all positive factors
VolitionRX (VNRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.34M
Dividend YieldN/A
Average Volume (3M)19.46M
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth86.32%
EPS Growth21.31%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-3.87
Shares Outstanding13,649,384
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside1547.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$2.21M
VolitionRX Business Overview & Revenue Model
Company Description
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screen...
How the Company Makes Money
VolitionRx makes money primarily by developing, selling, and licensing diagnostic tests and related reagents/kits based on its nucleosome (Nu.Q®) technology. Key revenue streams include: (1) Product revenue from selling diagnostic or research-use ...
VolitionRX Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Neutral
The call conveyed significant scientific and commercial progress: multiple clinical validations and publications, high‑profile collaborations (Sysmex, Werfen, Revvity, Hologic, Mayo Clinic), promising lateral flow point‑of‑care data (~90% correlation), Capture‑Seq publication and sizable TAM estimates, plus cost reductions (operating expenses down 32% YoY) and successful recent financing that increased cash to ~$2.8M. Counterbalancing these positives are a flat Q2 revenue ($0.4M), lumpy/ timing‑dependent revenue recognition, an increased net loss driven by noncash charges, ongoing peer‑review delays (impacting a $5M milestone), limited absolute cash on hand relative to quarterly cash burn, and remaining regulatory/reimbursement uncertainty. Overall, the call highlights strong technical and partnership momentum but also clear near‑term financial and execution risks.Positive Updates
Nu.Q NETs — Lateral Flow Prototype and Point-of-Care Progress
Demonstrated lateral flow prototype that quantifies nucleosomes from a finger‑prick (capillary) blood sample; correlation of ~90% versus the CE‑marked automated Nu.Q NETs assay. Enables rapid point‑of‑care identification of high‑risk sepsis patients and expands potential use cases into decentralized and low‑infrastructure settings (large addressable sepsis population cited ~166 million cases worldwide).
Negative Updates
Flat Q2 Revenue and Lumpy Revenue Recognition
Second quarter revenue was approximately $0.4 million, broadly flat versus Q2 2025. Revenue pattern described as uneven and 'lumpy' with no revenue guidance provided; timing of large orders and project deliveries impacts quarter‑to‑quarter results.
Read all updates
Q2-2026 Updates
Positive
Negative
Nu.Q NETs — Lateral Flow Prototype and Point-of-Care Progress
Demonstrated lateral flow prototype that quantifies nucleosomes from a finger‑prick (capillary) blood sample; correlation of ~90% versus the CE‑marked automated Nu.Q NETs assay. Enables rapid point‑of‑care identification of high‑risk sepsis patients and expands potential use cases into decentralized and low‑infrastructure settings (large addressable sepsis population cited ~166 million cases worldwide).
Read all positive updates
Company Guidance
The company said it will not provide full-year 2026 revenue guidance but expects year‑over‑year growth for the full year while noting quarterly revenue will remain lumpy (Q2 revenue ~$0.4M, Q1 ~$1.0M; H1 revenue $1.4M, +112% YoY) driven by a mix of product and deferred revenue (~50/50 in Q2 from the Heska agreement) and timing of Discover Services projects; operating discipline remains a priority with Q2 operating expenses down 32% YoY to $4.6M, a 27% reduction in headcount vs mid‑2025, net loss of $7.3M (impact from ~$3M noncash Lind note charge), net cash used in operations $5.2M (vs $6.3M prior year), cash of ~$2.8M at quarter end (vs $1.1M at 12/31/25) and Q2 cash inflows including ~$1.2M from the ATM and ~$4.1M from a public offering. Key near‑term milestones reiterated as guidance include a reimbursement submission for Nu.Q Lung Cancer in France in Q3, DETECSEPS enrollment starting September and completion of large sepsis and trauma studies (e.g., Mayo Clinic i10 placement this quarter — Mayo sees ~2,200 trauma patients/year); product/technical metrics highlighted that the lateral‑flow fingerprint prototype correlates ~90% with the CE‑marked venous assay, the feline Nu.Q Vet prototype shows 86% sensitivity at 97% specificity (publication expected to trigger a $5M milestone), Capture‑Seq addresses TAMs of ~$23B (multi‑cancer early detection) and >$13B (MRD), and global sepsis incidence cited at ~166M cases (sepsis‑related deaths reported at 31.5% of global deaths in 2021).VolitionRX Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.46M | 1.73M | 1.23M | 775.30K | 306.39K | 90.03K |
| Gross Profit | 2.20M | 1.73M | 1.23M | 775.30K | 306.39K | 90.03K |
| EBITDA | -16.79M | -19.80M | -25.58M | -34.04M | -29.24M | -25.69M |
| Net Income | -25.64M | -23.36M | -26.97M | -35.32M | -30.27M | -26.81M |
Balance Sheet | ||||||
| Total Assets | 8.30M | 6.90M | 9.40M | 27.95M | 18.30M | 27.49M |
| Cash, Cash Equivalents and Short-Term Investments | 2.79M | 1.12M | 3.26M | 20.73M | 10.87M | 20.58M |
| Total Debt | 1.77M | 11.46M | 5.82M | 5.86M | 4.97M | 4.02M |
| Total Liabilities | 28.35M | 42.49M | 35.51M | 36.66M | 21.42M | 9.77M |
| Stockholders Equity | -20.05M | -34.25M | -24.91M | -7.80M | -2.57M | 17.94M |
Cash Flow | ||||||
| Free Cash Flow | -19.43M | -19.77M | -26.47M | -19.15M | -16.85M | -21.83M |
| Operating Cash Flow | -19.40M | -19.68M | -25.89M | -18.06M | -15.28M | -20.85M |
| Investing Cash Flow | -20.80K | -89.56K | -573.85K | -1.08M | -1.57M | -973.56K |
| Financing Cash Flow | 20.21M | 17.09M | 8.66M | 28.98M | 6.94M | 22.86M |
VolitionRX Technical Analysis
Negative
0.85
Price Trends
1.15
Negative
2.05
Negative
3.82
Negative
Market Momentum
-0.18
Negative
21.21
Positive
8.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.83, below the 50-day MA of 1.15, and below the 200-day MA of 3.82, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 21.21 is Positive, neither overbought nor oversold. The STOCH value of 8.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNRX.
VolitionRX Risk Analysis
VolitionRX disclosed 35 risk factors in its most recent earnings report. VolitionRX reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VolitionRX Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $253.23M | -7.57 | -788.19% | ― | 34.46% | 43.48% | |
55 Neutral | $42.00M | -36.15 | -6.73% | ― | 28.04% | 43.26% | |
52 Neutral | $13.90M | -0.32 | -71.38% | ― | 10.03% | 91.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $92.88M | -1.06 | -10.96% | ― | -0.21% | 75.40% | |
45 Neutral | $7.34M | -0.14 | 74.16% | ― | 86.32% | 21.31% | |
41 Neutral | $7.52M | -0.19 | 68.09% | ― | -13.28% | 39.65% |
* Healthcare Sector Average
VNRX
VolitionRX
0.54
-13.13
-96.07%
TRIB
Trinity Biotech
11.67
-35.43
-75.22%
PRPO
Precipio
23.50
9.20
64.34%
BNGO
BioNano Genomics
1.18
-1.97
-62.54%
BNR
Burning Rock Biotech
8.83
-1.34
-13.18%
BDSX
Biodesix
24.00
15.50
182.35%
VolitionRX Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
VolitionRx Shareholders Approve Governance and Capital Changes
Positive
Jul 21, 2026
On July 17, 2026, VolitionRx held its annual meeting of stockholders in London, where shareholders elected seven directors to serve until the next annual meeting and ratified Sadler, Gibb Associates, LLC as the independent registered public accou...
Business Operations and StrategyPrivate Placements and Financing
VolitionRx Converts Debt to Equity Through Share Issuances
Positive
Jun 18, 2026
VolitionRx Limited disclosed that, under a senior secured convertible promissory note originally issued to Lind Global Asset Management XII LLC for $7.5 million pursuant to a securities purchase agreement, it has recently made share-based repaymen...
Private Placements and FinancingRegulatory Filings and Compliance
VolitionRx Secures Waiver on Convertible Note Covenant Breach
Negative
May 22, 2026
On May 21, 2026, VolitionRx and Lind Global Asset Management XII LLC entered into a waiver and consent after the company breached a covenant requiring it to maintain a minimum market capitalization under senior secured convertible notes issued in ...
Executive/Board ChangesShareholder Meetings
VolitionRx Announces Board Streamlining as Director Departs
Neutral
May 15, 2026
On May 12, 2026, VolitionRx Limited disclosed that board member Mickie Henshall, who has served since August 2022, will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders, with the company noting that her decision...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.